QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development.

In 1997, the Committee for Proprietary Medicinal Products (CPMP) issued a document concerning the potential of non-cardiovascular drugs to cause prolongation of the QT interval of the electrocardiogram. This article reviews several aspects of this complex problem, including a preclinical strategy (in vitro electrophysiology in human cardiac cells and in vivo pharmacologically validated conscious dogs) to satisfy the expectations of the CPMP. In particular, the discussion stresses the danger of drugs prolonging the QT interval in patients with concurrent cardiac risk factors and the need for rigorous clinical testing to determine the risk of fatal cardiac events for drugs with the propensity to prolong QT.

[1]  Vincent Gm,et al.  The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. , 1998 .

[2]  J. Lynch,et al.  Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. , 1995, Circulation research.

[3]  A Varró,et al.  Delayed rectifier potassium current in undiseased human ventricular myocytes. , 1998, Cardiovascular research.

[4]  L. Furness,et al.  Pharmacogenomics - it's not just pharmacogenetics. , 1998, Current opinion in biotechnology.

[5]  S Nattel,et al.  Potential molecular basis of different physiological properties of the transient outward K+ current in rabbit and human atrial myocytes. , 1999, Circulation research.

[6]  T. Stern,et al.  The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review. , 1995, Psychosomatics.

[7]  W. Crumb,et al.  Description of a nonselective cation current in human atrium. , 1995, Circulation research.

[8]  J. Towbin,et al.  Molecular genetics of long QT syndrome from genes to patients. , 1997, Current opinion in cardiology.

[9]  T. Yamamoto,et al.  Blockage by terfenadine of the adenosine triphosphate (ATP)-sensitive K+ current in rabbit ventricular myocytes. , 1998, The Journal of pharmacology and experimental therapeutics.

[10]  J J Heger,et al.  Sudden cardiac death. , 1998, Circulation.

[11]  S. Priori.  Exploring the Hidden Danger of Noncardiac Drugs , 1998, Journal of cardiovascular electrophysiology.

[12]  C T Dollery.  Drug discovery and development in the molecular era. , 1999, British journal of clinical pharmacology.

[13]  D. Roden,et al.  Torsade de pointes , 1993, Clinical cardiology.

[14]  D. Mckinnon,et al.  Quantitative analysis of potassium channel mRNA expression in atrial and ventricular muscle of rats. , 1994, Circulation research.

[15]  S. Nattel,et al.  Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. , 1997, Circulation research.

[16]  H. Refsum,et al.  Rate‐Dependent Class III Antiarrhythmic Action, Negative Chronotropy, and Positive Inotropy of a Novel Ik Blocking Drug, UK‐68,798: Potent in Guinea Pig but no Effect in Rat Myocardium , 1990, Journal of cardiovascular pharmacology.

[17]  J A Kors,et al.  Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. , 1999, European heart journal.

[18]  Y. Ukai,et al.  Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs. , 1998, General pharmacology.

[19]  D. Snyders,et al.  Electrophysiological and pharmacological correspondence between Kv4.2 current and rat cardiac transient outward current. , 1997, Cardiovascular research.

[20]  M. Keating,et al.  The long QT syndrome. A review of recent molecular genetic and physiologic discoveries. , 1996, Medicine.

[21]  D. Zipes,et al.  In Vivo and In Vitro Electrophysiologic Effects of Terodiline on Dog Myocardium , 1995, Journal of cardiovascular electrophysiology.

[22]  D. Mckinnon,et al.  Role of the Kv4.3 K+ channel in ventricular muscle. A molecular correlate for the transient outward current. , 1996, Circulation research.

[23]  R. Gilmour,et al.  Decreased Density of Ito in Left Ventricular Myocytes from German Shepherd Dogs with Inherited Arrhythmias , 1997, Journal of cardiovascular electrophysiology.

[24]  A. Brown,et al.  Molecular determinants of dofetilide block of HERG K+ channels. , 1998, Circulation research.

[25]  M. Morad,et al.  Comparative effects of loratadine and terfenadine on cardiac K+ channels. , 1997, Journal of cardiovascular pharmacology.

[26]  D. Roden,et al.  Cisapride‐Induced Torsades de Pointes , 1998, Journal of cardiovascular electrophysiology.

[27]  A. Brown,et al.  Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. , 1996, Circulation.

[28]  H. Just,et al.  Drug-Induced Torsade de Pointes , 1994, Drug safety.

[29]  J. Camm,et al.  The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. , 1998, European heart journal.

[30]  P E Puddu,et al.  The shape of human atrial action potential accounts for different frequency-related changes in vitro. , 1996, International journal of cardiology.